全文获取类型
收费全文 | 293篇 |
免费 | 23篇 |
国内免费 | 2篇 |
专业分类
儿科学 | 16篇 |
妇产科学 | 9篇 |
基础医学 | 66篇 |
口腔科学 | 5篇 |
临床医学 | 14篇 |
内科学 | 46篇 |
皮肤病学 | 3篇 |
神经病学 | 15篇 |
特种医学 | 23篇 |
外科学 | 30篇 |
综合类 | 8篇 |
预防医学 | 13篇 |
药学 | 8篇 |
肿瘤学 | 62篇 |
出版年
2023年 | 5篇 |
2021年 | 7篇 |
2020年 | 7篇 |
2019年 | 8篇 |
2018年 | 33篇 |
2017年 | 20篇 |
2016年 | 12篇 |
2015年 | 16篇 |
2014年 | 12篇 |
2013年 | 11篇 |
2012年 | 14篇 |
2011年 | 13篇 |
2010年 | 12篇 |
2009年 | 16篇 |
2008年 | 10篇 |
2007年 | 12篇 |
2006年 | 7篇 |
2005年 | 8篇 |
2004年 | 3篇 |
2003年 | 7篇 |
2002年 | 8篇 |
2001年 | 6篇 |
2000年 | 4篇 |
1999年 | 4篇 |
1998年 | 11篇 |
1997年 | 12篇 |
1996年 | 4篇 |
1995年 | 5篇 |
1994年 | 4篇 |
1993年 | 9篇 |
1992年 | 2篇 |
1989年 | 1篇 |
1988年 | 1篇 |
1987年 | 3篇 |
1986年 | 4篇 |
1985年 | 1篇 |
1983年 | 2篇 |
1981年 | 3篇 |
1979年 | 1篇 |
排序方式: 共有318条查询结果,搜索用时 15 毫秒
1.
Arthur I. Kooyker Esther Toes-Zoutendijk Annemieke W.J. Opstal-van Winden Manon C.W. Spaander Maaike Buskermolen Hanneke J. van Vuuren Ernst J. Kuipers Folkert J. van Kemenade Chris Ramakers Maarten G.J. Thomeer Evelien Dekker Iris D. Nagtegaal Harry J. de Koning Monique E. van Leerdam Iris Lansdorp-Vogelaar 《International journal of cancer. Journal international du cancer》2020,147(4):1098-1106
The Dutch colorectal cancer (CRC) screening program started in 2014, inviting the target population biennially to perform a fecal immunochemical test (FIT). We obtained prospectively collected data from the national screening information-system to present the results of the second round (2016) and evaluate the impact of increasing the FIT cut-off halfway through the first round from 15 to 47 μg Hb/g feces on outcomes in the second round. Second round screening was done with a 47 μg Hb/g feces FIT cut-off. Participants were classified based on first round participation status as either FIT (15,47) or FIT (47,47) participants, and previous nonparticipants. In total, 348,891 (75.9%) out of 459,740 invitees participated in the second round. Participation rates were 93.4% among previous participants and 21.0% among previous non-participants. FIT(47,47) participants had a significantly higher detection rate of AN (15.3 vs. 10.4 per 1,000 participants) compared to FIT(15,47) participants in the second round, while their cumulative detection rate of AN over two rounds was significantly lower (45.6 vs. 52.6 per 1,000 participants). Our results showed that participation in the Dutch CRC screening program was consistently high and that second round detection rates depended on the first round FIT cut-off. The cumulative detection over two rounds was higher among FIT(15,47) participants. These findings suggest that a substantial part of, but not all the missed findings in the first round due to the increased FIT cut-off were detected in the subsequent round. 相似文献
2.
Chemoradiation therapy for rectal cancer in the distal rectum followed by organ‐sparing transanal endoscopic microsurgery (CARTS study) 下载免费PDF全文
3.
4.
5.
Niek Hugen Femke Simmer Leonie J.M. Mekenkamp Miriam Koopman Evert van den Broek Johannes H.W. de Wilt Cornelis J.A. Punt Bauke Ylstra Gerrit A. Meijer Iris D. Nagtegaal 《Oncotarget》2015,6(28):25715-25725
Background
Mucinous carcinoma (MC) is found in 10%–15% of colorectal cancer (CRC) patients. It differs from the common adenocarcinoma (AC) in histopathological appearance and clinical behavior.Methods
Genome-wide DNA copy number and survival data from MC and AC primary CRC samples from patients from two phase III trials (CAIRO and CAIRO2) was compared. Chromosomal copy number data from The Cancer Genome Atlas (TCGA) was used for validation. Altogether, 470 ACs were compared to 57 MCs.Results
MC showed a reduced amount of copy number aberrations (CNAs) compared with AC for the CAIRO/CAIRO2 cohort, with a median amount of CNAs that was 1.5-fold lower (P = 0.002). Data from TCGA also showed a reduced amount of CNAs for MC. MC samples in both cohorts displayed less gain at chromosome 20q and less loss of chromosome 18p. A high rate of chromosomal instability was a strong negative prognostic marker for survival in MC patients from the CAIRO cohorts (hazard ratio 15.60, 95% CI 3.24–75.05).Conclusions
Results from this study indicate that the distinct MC phenotype is accompanied by a different genetic basis when compared with AC and show a strong association between the rate of chromosomal instability and survival in MC patients. 相似文献6.
7.
8.
9.
J.?J.?VehreschildEmail authorView authors OrcID profile C.?P.?Heussel A.?H.?Groll M.?J.?G.?T.?Vehreschild G.?Silling G.?Würthwein M.?Brecht O.?A.?Cornely 《European radiology》2017,27(8):3275-3282
Background
Serial chest CT is the standard of care to establish treatment success in invasive pulmonary aspergillosis (IPA). Data are lacking how response should be defined.Methods
Digital CT images from a clinical trial on treatment of IPA were re-evaluated and compared with available biomarkers. Total volume of pneumonia was added up after manual measurement of each lesion, followed by statistical analysis.Results
One-hundred and ninety CT scans and 309 follow-up datasets from 40 patients were available for analysis. Thirty-one were neutropenic. Baseline galactomannan (OR 4.06, 95%CI: 1.08–15.31) and lesion volume (OR 3.14, 95%CI: 0.73–13.52) were predictive of death. Lesion volume at d7 and trend between d7 and d14 were strong predictors of death (OR 20.01, 95%CI: 1.42–282.00 and OR 15.97, 95%CI: 1.62–157.32) and treatment being rated as unsuccessful (OR 4.75, 95%CI: 0.94–24.05 and OR 40.69, 95%CI: 2.55–649.03), which was confirmed by a Cox proportional hazards model using time-dependent covariates.Conclusion
Any increase in CT lesion volume between day 7 and day 14 was a sensitive marker of a lethal outcome (>50%), supporting a CT rescan each one and 2 weeks after initial detection of IPA. The predictive value exceeded all other biomarkers. Further CT follow-up after response at day 14 was of low additional value.Key Points
? CT evaluation offers good prediction of outcome for invasive pulmonary aspergillosis.? Predictive capability exceeds galactomannan, blood counts, and lesion count.? Any progression between day 7 and day 14 constitutes a high-risk scenario.10.